A Prospective Clinical Trial Comparing Surgical Fixation Versus Nonoperative Management of Minimally Displaced Complete Lateral Compression Pelvis Fractures.


Journal

Journal of orthopaedic trauma
ISSN: 1531-2291
Titre abrégé: J Orthop Trauma
Pays: United States
ID NLM: 8807705

Informations de publication

Date de publication:
01 Nov 2021
Historique:
accepted: 05 02 2021
pubmed: 17 5 2021
medline: 26 10 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

To compare the early pain and functional outcomes of operative fixation versus nonoperative management for minimally displaced complete lateral compression (LC; OTA/AO 61-B1/B2) pelvic fractures. Prospective clinical trial. Two academic trauma centers. Forty-eight adult patients with LC pelvic ring injuries with <10 mm of displacement were treated nonoperatively and 47 with surgical fixation. Sixty percent of participants were randomized. Seventy-three percent of the fractures were displaced <5 mm, and 71% were LC-1 patterns. Operative fixation versus nonoperative management. The primary outcome was patient-reported pain using the 10-point Brief Pain Inventory. Functional outcome was measured using the Majeed pelvic score. Outcomes were analyzed using hierarchical Bayesian models to compare the average treatment effect from injury to 12 and 52 weeks postinjury. The probability of the mean treatment benefit exceeding a clinically important difference was determined. The 3-month average treatment effect of surgery compared with nonoperative management was a 1.2-point reduction in pain [95% credible interval (CrI): 0.4-1.9] and an 8% absolute improvement in the Majeed score (95% CrI: 3%-14%). Similar results persisted to 1 year. Patients with initial fracture displacement ≥5 mm experienced a larger reduction in pain (2.2, 95% CrI: 0.9-3.5) compared with those patients with less initial displacement (0.9, 95% CrI: 0.1-1.8). On average, surgical fixation likely provides a small improvement in pain and functional outcome for up to 12 months. Patients with ≥5 mm of posterior pelvic ring displacement are more likely to experience clinically important improvements in pain. Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

Identifiants

pubmed: 33993178
doi: 10.1097/BOT.0000000000002088
pii: 00005131-202111000-00007
doi:

Banques de données

ClinicalTrials.gov
['NCT02625766']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

592-598

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflict of interest.

Références

Sembler Soles GL, Lien J, Tornetta P 3rd. Nonoperative immediate weightbearing of minimally displaced lateral compression sacral fractures does not result in displacement. J Orthop Trauma. 2012;26:563–567.
Bruce B, Reilly M, Sims S. OTA highlight paper predicting future displacement of nonoperatively managed lateral compression sacral fractures: can it be done? J Orthop Trauma. 2011;25:523–527.
McLaren AC, Rorabeck CH, Halpenny J. Long-term pain and disability in relation to residual deformity after displaced pelvic ring fractures. Can J Surg. 1990;33:492–494.
Templeman DC, Simpson T, Matta JM. Surgical management of pelvic ring injuries. Instr Course Lect. 2005;54:395–400.
Tornetta P 3rd, Matta JM. Outcome of operatively treated unstable posterior pelvic ring disruptions. Clin Orthop Relat Res. 1996:186–193.
Tornetta P 3rd, Lowe JA, Agel J, et al. Does operative intervention provide early pain relief for patients with unilateral sacral fractures and minimal or No displacement? J Orthop Trauma. 2019;33:614–618.
Gaski GE, Manson TT, Castillo RC, et al. Nonoperative treatment of intermediate severity lateral compression type 1 pelvic ring injuries with minimally displaced complete sacral fracture. J Orthop Trauma. 2014;28:674–680.
Hagen J, Castillo R, Dubina A, et al. Does surgical stabilization of lateral compression-type pelvic ring fractures decrease patients' pain, reduce narcotic use, and improve mobilization? Clin Orthop Relat Res. 2016;474:1422–1429.
Meinberg EG, Agel J, Roberts CS, et al. Fracture and dislocation classification compendium—2018. J Orthop Trauma. 2018;32(suppl 1):S1–S170.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief pain inventory. Ann Acad Med Singapore. 1994;23:129–138.
Tashjian RZ, Deloach J, Porucznik CA, et al. Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. J Shoulder Elbow Surg. 2009;18:927–932.
Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol. 2007;34:1674–1683.
Crossley KM, Bennell KL, Cowan SM, et al. Analysis of outcome measures for persons with patellofemoral pain: which are reliable and valid? Arch Phys Med Rehabil. 2004;85:815–822.
Majeed SA. Grading the outcome of pelvic fractures. J Bone Joint Surg Br. 1989;71:304–306.
Lefaivre KA, Slobogean GP, Ngai JT, et al. What outcomes are important for patients after pelvic trauma? Subjective responses and psychometric analysis of three published pelvic-specific outcome instruments. J Orthop Trauma. 2014;28:23–27.
Rubin DB. Inference and missing data. Biometrika. 1976;63:581–592.
Griffin DR, Dickenson EJ, Wall PDH, et al. Hip arthroscopy versus best conservative care for the treatment of femoroacetabular impingement syndrome (UK FASHIoN): a multicentre randomised controlled trial. Lancet. 2018;391:2225–2235.
Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) Investigators. Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial. Lancet. 2017;389:1519–1527.
Launonen AP, Sumrein BO, Reito A, et al. Operative versus non-operative treatment for 2-part proximal humerus fracture: a multicenter randomized controlled trial. PLoS Med. 2019;16:e1002855.

Auteurs

Gerard P Slobogean (GP)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Greg E Gaski (GE)

Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN; and.

Jason Nascone (J)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Marcus F Sciadini (MF)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Roman M Natoli (RM)

Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN; and.

Theodore T Manson (TT)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Christopher Lebrun (C)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Todd McKinley (T)

Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN; and.

Walter W Virkus (WW)

Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN; and.

Anthony T Sorkin (AT)

Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN; and.

Krista Brown (K)

Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN; and.

Andrea Howe (A)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Joshua Rudnicki (J)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Blessing Enobun (B)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Nathan N O'Hara (NN)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Jeff Gill (J)

Department of Mathematics and Statistics, American University, Washington, DC.

Robert V O'Toole (RV)

Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH